Format

Send to

Choose Destination
  • PMID: 21505310 was deleted because it is a duplicate of PMID: 21537116
AIDS. 2011 May 15;25(8):1131-3. doi: 10.1097/QAD.0b013e3283471d83.

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse.

Author information

1
Hospital Carlos III, Madrid, Spain.

Abstract

IL28B polymorphisms predict treatment response in chronic hepatitis C. However, no information exists in prior treatment failures. A total of 62 HIV/hepatitis C virus (HCV) patients who completed retreatment with peginterferon-α/ribavirin were examined, of whom 25 (40%) had been cured. Predictors of response [odds ratio, OR (95% confidence interval, CI)] were HCV genotypes 2/3 [16.1 (2.7-90.9)], prior relapse [9.6 (1.5-62.4)] and ribavirin plasma trough concentrations at week 4 [4.9 (1.3-18.4)]. IL28B-CC only predicted response in prior nonresponders carrying HCV genotypes 1/4 [25.1 (1.9-337)].

PMID:
21537116
DOI:
10.1097/QAD.0b013e3283471d83
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center